Fig. 3
From: TGF-β1-triggered maladaptive bone marrow endothelium impedes hematopoietic recovery

RNA-seq analysis revealed that TGF-β1 treatment induces a shift in the secretome of BM ECs. a Illustrative diagram of the RNA-seq analysis of BM ECs treated with or without TGF-β1. Certain elements of this figure were created with BioRender.com (www.biorender.com). b Distributions and quantifications of the genes in the indicated groups. The x-axis shows the log2 of the change in gene expression between the TGF-β1 group and the control group, whereas the y-axis represents -log₁₀(adjusted p value). c GO biological process analysis revealed the top significant GO terms in BM ECs treated with TGF-β1. The z-score is calculated as (number of up genes - number of down genes) divided by the square root of the total number of genes. d Network analysis revealed the enriched terms in BM ECs treated with TGF-β1. Each node within the network signifies an enriched term. Nodes are interconnected by edges when the associated terms display a similarity exceeding 0.3. The color of each node reflects its cluster ID, while the node’s size is determined by the number of genes included in the corresponding term. e The top 5 HALLMARK pathways enriched in BM ECs in the TGF-β1 group according to GSEA. f Venn diagram showing a significantly increased proportion of secretory proteins in BM ECs treated with TGF-β1. g KEGG analysis revealed the top significant pathways enriched with the differentially expressed genes encoding secretory proteins in BM ECs from the TGF-β1 group